Comparative Pharmacology
Head-to-head clinical analysis: CARTIA XT versus DYNACIRC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARTIA XT versus DYNACIRC.
CARTIA XT vs DYNACIRC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem, a benzothiazepine calcium channel blocker, inhibits calcium ion influx across cardiac and vascular smooth muscle cells during depolarization, leading to vasodilation and reduced myocardial contractility and conduction velocity, particularly at the AV node.
Dynacirc (isradipine) is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced peripheral vascular resistance, thereby lowering blood pressure.
Diltiazem hydrochloride extended-release capsules (CARTIA XT) are administered orally. For hypertension and angina, the typical adult dose is 180–360 mg once daily, initially 180 mg once daily, titrated to response.
2.5-10 mg orally once daily; titrate based on response. Maximum 20 mg/day.
None Documented
None Documented
Terminal half-life 3-4.5 hours; prolonged in hepatic impairment (up to 15 hours) or with cimetidine.
Terminal elimination half-life is 7-8 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged up to 14 hours, necessitating dose adjustment.
Renal (biliary/fecal minimal). 70-80% excreted as inactive metabolites in urine; 15% unchanged.
Primarily hepatic metabolism (CYP3A4) with <1% excreted unchanged in urine; approximately 60% of metabolites are excreted in feces via bile, and 35% in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker